Bismuth Patents (Class 424/653)
  • Patent number: 10266818
    Abstract: Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease. Further provided herein are pharmaceutical compositions comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof to treat bacterial infections of the gastrointestinal tract, such as C. difficile or H. pylori. Further provided herein are compositions comprising recombinant nepenthesin I or nepenthesin II, or homologous proteins, and methods for making the same.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 23, 2019
    Assignee: NEPETX, LLC
    Inventors: David C. Schriemer, Petr Man, Hynek Mrazek, Martial Rey
  • Patent number: 10039835
    Abstract: A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: August 7, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Daniel Jerome White, Jr., Michael Selden Godlewski, Timothy Charles Gulbin, Graham John Myatt
  • Patent number: 10034888
    Abstract: A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: July 31, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Steven Ray Gilbert, Edward Paul Fitch, V, Derrick Ho, Daniel Jerome White, Jr., Adam Michael Tunis
  • Patent number: 9943537
    Abstract: Provided is a novel method for treating a cancer using an FTD/TPI combination drug, which shows remarkably excellent antitumor effect and small adverse effects. An antitumor agent, in which a combination drug containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 and an anti-VEGF antibody or anti-EGFR antibody are administered in combination.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: April 17, 2018
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Hiroyuki Okabe
  • Patent number: 9895439
    Abstract: Pharmaceutical composition comprising a chemotherapeutic drug and a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug in vivo, in a pharmaceutically acceptable carrier or vehicle. The chemotherapeutic drug is selected from those able to induce over expression of netrin-1 in cancer cells. The combination is associated with synergic anti-cancer effect.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: February 20, 2018
    Assignee: NETRIS PHARMA
    Inventors: Patrick Mehlen, Andréa Paradisi, Pascale Nony
  • Patent number: 9789101
    Abstract: A pharmaceutical composition can include dyclonine hydrochloride and 4-methyl-1-(2-phenylethyl)-8-phenoxy-2,3-dihydro-1H-pyrrolo[3,2-c]-quinoline.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: October 17, 2017
    Assignee: HELPERBY THERAPEUTICS LIMITED
    Inventors: Yanmin Hu, Anthony M. R. Coates
  • Patent number: 9623092
    Abstract: Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: April 18, 2017
    Assignee: NEPETX, LLC
    Inventor: David Schriemer
  • Patent number: 9566334
    Abstract: The invention provides combinations comprising GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof and ME-HD7945A. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer (e.g., triple negative breast cancer).
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: February 14, 2017
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Jose Baselga, Maurizio Scaltriti
  • Patent number: 9486436
    Abstract: A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 8, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Steven Ray Gilbert, Edward Paul Fitch, V, Derrick Ho, Daniel Jerome White, Jr., Adam Michael Tunis
  • Patent number: 9486460
    Abstract: A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 8, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Daniel Jerome White, Jr., Michael Selden Godlewski, Timothy Charles Gulbin, Graham John Myatt
  • Patent number: 9408393
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural and artificial surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: August 9, 2016
    Assignee: Microbion Corporation
    Inventor: Brett Hugh James Baker
  • Patent number: 9265722
    Abstract: Pharmaceutical compositions of a botulinum toxin for oral administration to a patient with a gastrointestinal disorder.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: February 23, 2016
    Assignee: Allergan, Inc.
    Inventor: Stephen Donovan
  • Patent number: 9131686
    Abstract: Microbicidal compositions that exhibit enhanced microbial efficacy are disclosed, as well as methods of producing and using the microbicidal compositions.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: September 15, 2015
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Laura S. Uretsky, Kevin Horan
  • Patent number: 9028878
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: May 12, 2015
    Assignee: Microbion Corporation
    Inventor: Brett Hugh James Baker
  • Patent number: 8852561
    Abstract: Fluoride varnish compositions for temporary application and adhesion to a person's teeth. The composition includes a carrier comprising a resin and an adhesion promoting agent comprising an alkyl phosphoric acid. A fluoride ion source (e.g., a fluoride salt such as sodium fluoride) is dispersed within the carrier so as to provide biologically available fluoride ions to the tooth tissue being treated. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and/or other factors.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 7, 2014
    Assignee: Ultradent Products, Inc.
    Inventors: Jeff A. Wagner, Andy T. Kawamoto
  • Publication number: 20140271921
    Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.
    Type: Application
    Filed: May 28, 2014
    Publication date: September 18, 2014
    Applicant: SLA PHARMA AG
    Inventor: DAVID NIGEL ARMSTRONG
  • Patent number: 8821906
    Abstract: The present disclosure relates to a biocompatible polymer composition for an article comprising a surface intended to contact blood, tissue, skin, epithelial layers, wounds, cells in culture fluids, body fluids, dialysis fluids, therapeutic fluids, or mixtures thereof for removal or infusion. The invention also relates to a method for the preparation of an article comprising the biocompatible polymer composition and a use thereof.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: September 2, 2014
    Assignee: Gambro Lundia AB
    Inventors: Reinhold Deppisch, Ruth Dietrich, Werner Beck, Andrea Schnell, Bernd Wittner
  • Publication number: 20140220152
    Abstract: Disclosed herein is a non-human animal model of protein aggregation cardiomyopathy. Also disclosed are compositions and methods of treating or preventing a condition in a subject caused or exacerbated by reductive stress. Also disclosed are compositions and methods of predicting, detecting, or monitoring reductive stress in a subject.
    Type: Application
    Filed: September 12, 2013
    Publication date: August 7, 2014
    Applicant: University of Utah Research Foundation
    Inventors: Ivor J. Benjamin, Namakal S. Rajasekaran, Thomas P. Kennedy
  • Publication number: 20140205682
    Abstract: The present invention relates to the a bismuth-based composition, particularly involving the use of bismuth ions, particularly the Bi+3 ion, for prevention and/or treatment of the haemolytic uremic syndrome, with the invention also relating to the use of a bismuth ion in the manufacture of a medicament for the prevention and/or treatment of an infection caused by a Shiga-toxin producing Escherichia coli strain, as well as to a method for preventing and/or treating the haemolytic uremic syndrome comprising administering bismuth ions to a patient in need thereof, and a method for inhibiting dissemination of the gene encoding virulence factors of a Shiga-toxin producing Escherichia coli strain in animals and humans.
    Type: Application
    Filed: October 10, 2011
    Publication date: July 24, 2014
    Applicant: SOUBEIRAN CHOBET S.R.L.
    Inventor: Hector Manuel Fernandez
  • Patent number: 8758831
    Abstract: An antiinfective-free formulation for prophylactic treatment of mastitis in dry cows comprises a seal formulation having approximately 65% by weight of bismuth sub-nitrate in a gel based on aluminum stearate. The seal formulation is prepared by adding the bismuth sub-nitrate to the gel base in at least two separate stages.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: June 24, 2014
    Assignee: Bimeda Research & Development Limited
    Inventors: Vincent McNally, Bridie Morgan
  • Publication number: 20140161901
    Abstract: Dental compositions are disclosed. A dental composition can include a reaction produce of a reaction mixture comprising a first mixture and a second mixture. The first mixture can include a ceramic based biomaterial, and the second mixture can include mineral trioxide aggregate and a phosphoric acid monomer.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 12, 2014
    Applicant: Zimmer Dental, Inc.
    Inventors: Jin Whan Lee, Hai Bo Wen, Jeffrey Bassett, Mike Warner
  • Patent number: 8691286
    Abstract: A composition for dissolving or reducing the viscosity of sputum on a surface of a device includes an effective amount of glycerol and an effective amount of dextran sulfate in a saline solution. The effective amount of glycerol is between about 30-50% and the effective amount of dextran sulfate is between about 10-30%. The composition may further include an antimicrobial agent.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: April 8, 2014
    Assignee: Teleflex Medical Incorporated
    Inventors: Nisha Gupta, Erin Peters, Joel Rosenblatt
  • Publication number: 20130316016
    Abstract: An antibacterial or anti-acne formulation suitable for topical or local application to human skin containing (a) either usnic acid or an usnate and (b) a metal salt selected from copper salts, bismuth salts, and mixtures thereof, wherein if the component (a) is an usnate, the components (a) and (b) are not the same compound.
    Type: Application
    Filed: December 20, 2011
    Publication date: November 28, 2013
    Applicant: EVOCUTIS PLC
    Inventors: Elizabeth Anne Eady, Daniel James Fitzgerald
  • Publication number: 20130302427
    Abstract: A medical device has a surface intended for contact with living tissue, wherein the surface comprises nanoparticles comprising a non-toxic post-transition metal such as gallium and/or bismuth, said nanoparticles having an average particle size of 500 nm or Less. The nanoparticles may provide an antimicrobial effect, and thus the risk for infection may be reduced.
    Type: Application
    Filed: May 2, 2013
    Publication date: November 14, 2013
    Applicant: DENTSPLY INTERNATIONAL INC.
    Inventors: Anna ARVIDSSON, Ingela MATTISSON, Elisabet AHLBERG, Johanna LÖBERG
  • Publication number: 20130302442
    Abstract: A method of treating a bacterial infection, e.g., a bacterial infection with methicillin resistant Staphylococcus aureus, Helicobacter pylori, Chlamydia trachomatis, or Chlamydia pneumonia, comprising administering to a subject (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide or a pharmaceutically acceptable salt thereof is disclosed. More specifically, a method of treating a bacterial infection comprising administering to a subject crystalline mono hydrochloride salt, crystalline mono mesylate salt or crystalline mono sulfate salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed.
    Type: Application
    Filed: May 14, 2013
    Publication date: November 14, 2013
    Applicants: Paratek Pharmaceuticals, Inc., Warmer Chilcott Company, LLC
    Inventors: Catherine Coulter, Sean M. Johnston, Farzaneh Seyedi, Tina M. deVries
  • Publication number: 20130266629
    Abstract: A medical device intended for contact with living tissue comprises a substrate having a surface, which surface comprises a layer comprising one or more compound(s)) of at least one non-toxic post-transition metal, such as a gallium or bismuth compound. A layer comprising a compound of a non-toxic post-transition metal has been shown to inhibit biofilm formation on the surface of the medical device, which may reduce the risk for infection e.g. around a dental implant. A method of producing the medical device comprises: a) providing a substrate having a surface; and applying a compound of a non-toxic post-transition metal onto said surface to form a layer, e.g. using a thin film deposition technique.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 10, 2013
    Applicant: DENTSPLY INTERNATIONAL INC.
    Inventor: Anna ARVIDSSON
  • Publication number: 20130238065
    Abstract: A phase change formulation includes a reversible phase change material and a thermal conductivity additive formulated for application to a user's epidermis.
    Type: Application
    Filed: March 6, 2012
    Publication date: September 12, 2013
    Applicant: EXERT CO.
    Inventor: Arvind M. Rao
  • Publication number: 20130209386
    Abstract: An antibacterial or anti-acne formulation containing (a) tropone or a substituted tropone and (b) a metal or metal salt selected from copper, copper salts, bismuth, bismuth salts, silver, silver salts, and mixtures thereof, for use in the treatment of either acne or body odour. The substituted tropone may be for example tropolone or hinokitiol.
    Type: Application
    Filed: July 25, 2011
    Publication date: August 15, 2013
    Applicant: EVOCUTIS PLC
    Inventors: Jonathan Cove, Daniel Fitzgerald, Nicholas Read
  • Patent number: 8486424
    Abstract: One embodiment includes a method including boiling unsalted butter over low heat until it appears golden to form purified butter; cooling the purified butter by removing it from the heat; straining or filtering the purified butter; refrigerating the purified butter for at least 24 hours; thoroughly blending together the elements of an organic carrier medium, wherein the organic carrier medium comprises the purified butter, olive oil, and honey; adding distilled water to the blended organic carrier medium; mixing the distilled water and the blended organic carrier medium at high speed; and adding at least one of sodium acid pyrophosphate, cornstarch, bismuth subnitrate, salicylic acid, or alkali metal salicylates, and mixing.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: July 16, 2013
    Inventor: Radmila Stojkoski
  • Patent number: 8486409
    Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: July 16, 2013
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Dangshe Ma, George Sgouros
  • Publication number: 20130149391
    Abstract: Fluoride varnish compositions for temporary application and adhesion to a person's teeth. The composition includes a carrier comprising a resin and an adhesion promoting agent comprising an alkyl phosphoric acid. A fluoride ion source (e.g., a fluoride salt such as sodium fluoride) is dispersed within the carrier so as to provide biologically available fluoride ions to the tooth tissue being treated. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and/or other factors.
    Type: Application
    Filed: February 7, 2013
    Publication date: June 13, 2013
    Applicant: Ultradent Products, Inc.
    Inventor: Ultradent Products, Inc.
  • Publication number: 20130129787
    Abstract: Described herein is the synthesis of adhesive complex coacervates from electrostatically associated block copolymers, wherein the block copolymers comprise alternating polycationic and polyanionic blocks. Methods for making and the using the adhesive complex coacervates are also described herein.
    Type: Application
    Filed: February 25, 2011
    Publication date: May 23, 2013
    Inventor: Russell J. Stewart
  • Patent number: 8389021
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: March 5, 2013
    Assignee: Microbion Corporation
    Inventor: Brett Hugh James Baker
  • Patent number: 8383163
    Abstract: Fluoride varnish compositions for temporary application and adhesion to a person's teeth. The composition includes a carrier comprising a resin and an adhesion promoting agent comprising an alkyl phosphoric acid. A fluoride ion source (e.g., a fluoride salt such as sodium fluoride) is dispersed within the carrier so as to provide biologically available fluoride ions to the tooth tissue being treated. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and/or other factors.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: February 26, 2013
    Assignee: Ultradent Products, Inc.
    Inventors: Jeff A. Wagner, Andy T. Kawamoto
  • Publication number: 20130039953
    Abstract: A method for treating a surface with a therapeutic agent is disclosed. The method comprises precipitating a therapeutic agent from a hydrophilic polymeric base layer with which the therapeutic agent has been complexed, to form a layer comprising microparticles of the therapeutic agent on the hydrophilic polymeric base layer, the hydrophilic polymeric base layer being grafted to the surface. Devices comprising a surface having a hydrophilic polymeric base layer comprising a hydrophilic polymer grafted to the surface and a layer comprising microparticles of a therapeutic agent disposed on and complexed with the hydrophilic polymeric base layer are also disclosed.
    Type: Application
    Filed: July 6, 2012
    Publication date: February 14, 2013
    Applicant: Covalon Technologies
    Inventors: Vyacheslav Dudnyk, Valerio DiTizio
  • Publication number: 20120269752
    Abstract: The invention relates to a cosmetic composition in particular in the form of an emulsion for topical application to keratin materials, in particular the skin, comprising, in a physiologically acceptable medium: (i) at least one dispersion (pre-dispersion) of bismuth oxychloride (CI 77163) in an oily dispersant chosen from a) monoesters of formula R1COOR2 in which R1 represents a linear or branched hydrocarbon-based chain comprising from 4 to 40 carbon atoms, preferably from 4 to 30 carbon atoms, and preferentially from 7 to 20 carbon atoms, and R2 represents a branched hydrocarbon-based chain containing from 3 to 40 carbon atoms, preferably from 10 to 30 carbon atoms, and preferentially from 16 to 26 carbon atoms; b) oils whose solubility parameter at 25° C., ?a, is greater than 6 (J/cm3)1/2, and mixtures thereof, and (ii) at least one oil chosen from hydrocarbon-based oils having a refractive index greater than 1.42 and a solubility parameter at 25° C.
    Type: Application
    Filed: July 2, 2010
    Publication date: October 25, 2012
    Applicant: L'OREAL
    Inventors: Emmanuelle Ozee, Laurence Guerchet, Xavier Blin, Nathalie Delattre
  • Publication number: 20120237566
    Abstract: The present invention relates to improved methods of preventing or inhibiting the release of acid in the stomach, which are uniquely reversible at the cellular level, through the use of organic isothiocyanates and thiocyanates with divalent cations such as barium, zinc and calcium for human and veterinary applications. The present invention also relates to methods of preventing or treating persistent chronic gastritis, GERDs, ulcer and or stomach cancer by inhibiting the release of stomach acid and by reducing inflammation with fewer and milder side-effects expected than current treatments. A method of screening therapeutics is described.
    Type: Application
    Filed: March 15, 2012
    Publication date: September 20, 2012
    Applicant: Venture Isles, LLC
    Inventors: Tushar K. Ray, Clyde G. Hanson, Paul Burgio
  • Patent number: 8216614
    Abstract: A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: July 10, 2012
    Assignee: The Board of Regents of the University of Texas Systems
    Inventors: Charles Y. C. Pak, Khashayar Sakhaee, Neill B. Walsdorf, Sr.
  • Publication number: 20120171276
    Abstract: A virus inactivating sheet is provided that can inactivate viruses adhering thereto even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The virus inactivating sheet can inactivate viruses adhering thereto and includes a sheet body, and monovalent copper compound fine particles and/or iodide fine particles that are held by the sheet body. The virus inactivating sheet can inactivate various viruses. These viruses can be inactivated even in the presence of lipids and proteins.
    Type: Application
    Filed: October 4, 2010
    Publication date: July 5, 2012
    Inventors: Yoshie Fujimori, Youhei Jikihara, Tetsuya Sato, Yoko Fukui, Tsuruo Nakayama
  • Publication number: 20120164139
    Abstract: Provided herein are methods of treating gastrointestinal motility disorders by targeting the dopamine 3 receptor (D3R). A D3R agonist is administered to a subject to decrease gastrointestinal motility to treat the disorder. A D3R antagonist is administered to a subject to decrease gastrointestinal motility to treat the disorder.
    Type: Application
    Filed: March 6, 2012
    Publication date: June 28, 2012
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Pankaj Jay Pasricha, Maria-Adelaide Micci
  • Publication number: 20110268819
    Abstract: An antiinfective-free formulation for prophylactic treatment of mastitis in dry cows comprises a seal formulation having approximately 65% by weight of bismuth sub-nitrate in a gel based on aluminium stearate. The seal formulation is prepared by adding the bismuth sub-nitrate to the gel base in at least two separate stages.
    Type: Application
    Filed: July 8, 2011
    Publication date: November 3, 2011
    Inventors: Vincent McNally, James Patrick Morgan, Bridie Morgan
  • Publication number: 20110195108
    Abstract: An antiviral agent is provided which can inactivate a wide range of viruses. Products that include such an antiviral agent are also provided. The present invention provides an antiviral agent that contains as an active ingredient a particle of at least one kind of iodide composed of iodine and an element shown in Period 4 to Period 6 and Group 8 to Group 15 of a periodic table or at least one kind of monovalent copper compound. The antiviral agent of the present invention can be designed at a higher degree of freedom in terms of its constituents as compared to conventional antiviral agents. In addition, the antiviral agent can readily exhibit and maintain its antiviral activity because it doesn't require any pretreatments or special washing processes.
    Type: Application
    Filed: August 31, 2009
    Publication date: August 11, 2011
    Inventors: Yoshie Fujimori, Tsuruo Nakayama, Tetsuya Sato
  • Publication number: 20110195130
    Abstract: Disclosed are various embodiments of edible food compositions effective for neutralizing stomach acid. Further, the present invention is directed toward methods of preparing the edible composition and the methods for reducing stomach acidity by ingesting the edible composition. In one embodiment, the edible composition comprises sweetener, flour, fat, leavening agent, water, and an effective amount of acid neutralizing material. In one embodiment, the above ingredients are combined to form a heavy dough which is then rolled out, divided into sections, and baked, resulting in a cookie with effective antacid properties. Further disclosed are edible compositions for delivering calcium as a dietary supplement.
    Type: Application
    Filed: February 9, 2010
    Publication date: August 11, 2011
    Inventor: Sanford Siegal
  • Patent number: 7887849
    Abstract: The invention relates to a pigment mixture consisting of at least two constituents, constituent A being uncoated, monocoated or multicoated glass lamellae, and constituent B being nacreous pigments based on phyllosilicates, SiO2 lamellae, Fe2O3 lamellae or Al2O3 lamellae. The invention also relates to the use of said pigment mixture, inter alia, in paints, dyes, especially printing inks, plastics, powder paints, pastes and cosmetic formulations.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: February 15, 2011
    Assignee: Merck Patent GmbH
    Inventors: Dieter Heinz, Ralf Anselmann, Klaus Boehm, Sabine Schoen
  • Publication number: 20100266647
    Abstract: Compositions comprising a gel system made from a combination of a fractal network of nanoparticles and translucent macroscopic particles, titanium dioxide and other color pigments is disclosed. The compositions are capable of forming an effective film on the biological surface such as skin to blurring fine lines and wrinkles while retaining a natural look of the skin as a consequence of synergy between the fractal particles, the macroscopic particles, titanium dioxide and color pigments. Also disclosed methods for their use.
    Type: Application
    Filed: November 14, 2008
    Publication date: October 21, 2010
    Applicant: AVON PRODUCTS, INC.
    Inventors: Ajay G. Dingley, Michael J. Fair, John R. Glynn, JR., Giovana A. Sandstrom
  • Publication number: 20100233269
    Abstract: A process for mineralizing a particulate organic material includes providing particles of a non-porous, swellable organic material, and contacting the particles with a solution containing at least one cation and a solution containing at least one anion, thereby obtaining the mineralized particulate organic material.
    Type: Application
    Filed: March 12, 2010
    Publication date: September 16, 2010
    Applicants: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Katarzyna Gorna, Andreas Goessl
  • Publication number: 20100189808
    Abstract: A composition for dissolving or reducing the viscosity of sputum on a surface of a device includes an effective amount of glycerol and an effective amount of dextran sulfate in a saline solution. The effective amount of glycerol is between about 30-50% and the effective amount of dextran sulfate is between about 10-30%. The composition may further include an antimicrobial agent.
    Type: Application
    Filed: January 26, 2010
    Publication date: July 29, 2010
    Applicant: TELEFLEX MEDICAL INCORPORATED
    Inventors: Nisha Gupta, Erin Peters, Joel Rosenblatt
  • Publication number: 20100189806
    Abstract: Methods of growing and harvesting multiple species of phytoplankton are disclosed herein. The method generally includes four steps, namely: (1) collecting phytoplankton seawater containing multiple species of naturally-occurring phytoplankton directly from a source of seawater; (2) adding nutrients to the phytoplankton seawater to proliferate the multiple species of naturally-occurring phytoplankton to a predetermined density; (3) separating the multiple species of naturally-occurring phytoplankton from the phytoplankton seawater to form a phytoplankton concentrate; and (4) collecting the phytoplankton concentrate such that the collected phytoplankton of the phytoplankton concentrate remain in a substantially intact cellular state.
    Type: Application
    Filed: October 21, 2009
    Publication date: July 29, 2010
    Inventors: Margaret Harper, Arturo Ramirez
  • Publication number: 20100135982
    Abstract: The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. Also included are solid dosage forms made from a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22.
    Type: Application
    Filed: February 3, 2010
    Publication date: June 3, 2010
    Inventors: Christopher E. Szymczak, James T. Walter
  • Publication number: 20100112091
    Abstract: The invention features a method of treating or preventing a disease associated with the use of antibiotics in a patient in need thereof by administering to the patient ramoplanin in an amount and for a duration effective to treat said disease. The disease may be caused, for example, by the presence of a bacterium such as enterotoxin producing strains of C. difficile, C. perfringens, or S. aureus.
    Type: Application
    Filed: September 10, 2009
    Publication date: May 6, 2010
    Inventors: Daniela Jabes, Timothy S. Leach, Richard F. Labaudiniere, Steven M. Rauscher, Giorgio Mosconi